Raymond James & Associates Acelrx Pharmaceuticals Inc Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 21, 2020	SELL	$0.76 - $2.07 $8,360 - $22,770	-11,000 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$1.66 - $2.4 $5,312 - $7,680	-3,200 Reduced 22.54%	11,000 $23,000
Q3 2019 Nov 07, 2019	BUY	$2.1 - $2.87 $1,470 - $2,009	700 Added 5.19%	14,200 $31,000
Q2 2019 Aug 06, 2019	SELL	$2.1 - $3.93 $34,650 - $64,845	-16,500 Reduced 55.0%	13,500 $34,000
Q1 2019 May 06, 2019	BUY	$2.35 - $3.83 $1,175 - $1,915	500 Added 1.69%	30,000 $104,000
Q4 2018 Feb 11, 2019	BUY	$2.13 - $4.8 $30,885 - $69,600	14,500 Added 96.67%	29,500 $68,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $4.6 $39,000 - $69,000	15,000 New	15,000 $58,000
Q4 2017 Feb 14, 2018	SELL	$1.75 - $5.5 $80,500 - $253,000	-46,000 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$2.9 - $4.6 $2,900 - $4,600	1,000 Added 2.22%	46,000 $212,000
Q2 2017 Aug 14, 2017	BUY	N/A	45,000	45,000 $97,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.